Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024		Sep. 30, 2025	Sep. 30, 2024
Revenue	$ 27,482	$ 25,204		$ 71,951	$ 65,833
Cost of revenue	3,278	2,453		9,158	6,410
Gross profit	24,204	22,751		62,793	59,423
Operating expenses:
Research and development expenses	14,008	11,355		52,793	42,251
Selling, general and administrative expenses	37,582	28,941		115,748	86,296
Operating loss	(27,386)	(17,545)		(105,748)	(69,124)
Financing on prepaid forward obligation	(4,621)	(5,915)		(13,848)	(17,348)
Interest expense on long-term debt	(3,373)	(2,721)		(11,573)	(8,629)
Interest and other income, net	979	2,599		4,392	5,922
Loss before income taxes	(34,401)	(23,582)		(126,777)	(89,179)
Income tax benefit (expense)	1,054	(91)		(353)	(183)
Net Loss	(33,347)	(23,673)		(127,130)	(89,362)
Statements of Comprehensive Loss
Net loss	(33,347)	(23,673)		(127,130)	(89,362)
Other comprehensive loss
Unrealized income (loss) on investments	17	267		(33)	224
Comprehensive Loss	$ (33,330)	$ (23,406)		$ (127,163)	$ (89,138)
Net loss per ordinary share - basic and diluted (in dollars per share)	$ (0.69)	$ (0.51)	[1]	$ (2.66)	$ (2.15)	[1]
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)	48,057,386	46,779,637	[1]	47,742,305	41,476,892	[1]

[1] The loss per share, both basic and diluted, for the third quarter of 2024 was revised to record an immaterial correction to the amounts originally reported in the September 30, 2024 Form 10-Q filed on November 6, 2024 by incorporating the 3,679,400 shares of pre-funded warrants outstanding as of the reporting period, which were not included in the previous calculations and are now reflected in the weighted average shares outstanding.